The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease
Open accessAbstract
Fabry disease is a lysosomal storage disorder caused by a deficiency of the lysosomal enzyme α-galactosidase A (α-gal A). This enzymatic defect results in the accumulation of the glycosphingolipid globotriaosylceramide (Gb 3 ; also referred to as ceramidetrihexoside) throughout the body. To investigate the effects of purified α-gal A, 10 patients with Fabry disease received a single i.v. infusion of one of five escalating dose levels of the enzyme. The objectives of this study were: ( i ) to evaluate the safety of administered α-gal A, ( ii ) to assess the pharmacokinetics of i.v.-administered α-gal A in plasma and liver, and ( iii ) to determine the effect of this replacement enzyme on hepatic, urine sediment and plasma concentrations of Gb 3 . α-Gal A infusions were well tolerated in all patients. Immunohistochemical staining of liver tissue approximately 2 days after enzyme infusion identified α-gal A in several cell types, including sinusoidal endothelial cells, Kupffer cells, and hepatocytes, suggesting diffuse uptake via the mannose 6-phosphate receptor. The tissue half-life in the liver was greater than 24 hr. After the single dose of α-gal A, nine of the 10 patients had significantly reduced Gb 3 levels both in the liver and shed renal tubular epithelial cells in the urine sediment. These data demonstrate that single infusions of α-gal A prepared from transfected human fibroblasts are both safe and biochemically active in patients with Fabry disease. The degree of substrate reduction seen in the study is potentially clinically significant in view of the fact that Gb 3 burden in Fabry patients increases gradually over decades. Taken together, these results suggest that enzyme replacement is likely to be an effective therapy for patients with this metabolic disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,385
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Kornfeld, S., & Mellman, I. (1989) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.05.110189.002411 · Cited by 1,580
Enzymatic Defect in Fabry's Disease: Ceramidetrihexosidase Deficiency
Brady, R. O., Gal, A. E., Bradley, R. M., Martensson, E., Warshaw, A. L., & Laster, L. (1967) · New England Journal of Medicine · doi:10.1056/nejm196705252762101 · Cited by 1,053
Self-citationImproved procedure for the extraction of lipids from human erythrocytes
Rose, H. G., & Oklander, M. (1965) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39314-7 · Cited by 1,033
Stahl, P., Schlesinger, P. H., Sigardson, E., Rodman, J. S., & Lee, Y. C. (1980) · Cell · doi:10.1016/0092-8674(80)90402-x · Cited by 569
Brady, R. O., Tallman, J. F., Johnson, W. G., Gal, A. E., Leahy, W. R., Quirk, J. M., & Dekaban, A. S. (1973) · New England Journal of Medicine · doi:10.1056/nejm197307052890103 · Cited by 312
Self-citationMannose 6-phosphate receptors in sorting and transport of lysosomal enzymes
Hille-Rehfeld, A. (1995) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(95)00004-b · Cited by 249
Mayes, J. S., Scheerer, J. B., Sifers, R. N., & Donaldson, M. L. (1981) · Clinica Chimica Acta · doi:10.1016/0009-8981(81)90384-3 · Cited by 218
Early renal changes in hemizygous and heterozygous patients with Fabry's disease
Gübler, M.-C., Lenoir, G., Grünfeld, J., Ulmann, A., Droz, D., Habib, R., Naizot, C., Adafer, E., & Grandhomme, C. (1978) · Kidney International · doi:10.1038/ki.1978.32 · Cited by 182
Overexpression of the Human Lysosomal Enzyme α-L-Iduronidase in Chinese Hamster Ovary Cells
Kakkis, E., Matynia, A., Jonas, A. J., & Neufeld, E. F. (1994) · Protein Expression and Purification · doi:10.1006/prep.1994.1035 · Cited by 91
Cited by
Glycosylation in health and disease
Reily, C., Stewart, T. J., Renfrow, M. B., & Novak, J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0129-4 · Cited by 2,075
Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., & Desnick, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450102 · Cited by 1,559
Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial
Schiffmann, R., Kopp, J. B., Austin III, H. A., Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., & Brady, R. O. (2001) · JAMA · doi:10.1001/jama.285.21.2743 · Cited by 1,302
Self-citationFabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
Mehta, A., Ricci, R., Widmer, U., Dehout, F., Garcia de Lorenzo, A., Kampmann, C., Linhart, A., Sunder‐Plassmann, G., Ries, M., & Beck, M. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01309.x · Cited by 848
Desnick, R. J., Brady, R., Barranger, J., Collins, A. J., Germain, D. P., Goldman, M., Grabowski, G., Packman, S., & Wilcox, W. R. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-4-200302180-00014 · Cited by 766
Self-citation
Metadata
- Authors
- Schiffmann, R., Murray, G. J., Treco, D., Daniel, P., Sellos-Moura, M., Myers, M., Quirk, J. M., Zirzow, G. C., Borowski, M., Loveday, K., Anderson, T., Gillespie, F., Oliver, K. L., Jeffries, N. O., Doo, E., Liang, T. J., Kreps, C., Gunter, K., Frei, K., Crutchfield, K., Selden, R. F., & Brady, R. O.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-01-04
- Volume
- 97
- Issue
- 1
- Pages
- 365-370
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2084201369
- Cited by
- 342
- References
- 13
- FWCI
- 16.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.